PT - JOURNAL ARTICLE AU - JUNAN LI AU - NATHAN SELIGSON AU - XUEJIE ZHANG AU - JASMINE JOHNSON AU - ZACHARY VANGUNDY AU - DANXING WANG AU - MITCH PHELPS AU - CRAIG HOFMEISTER AU - WOLFGANG SADEE AU - MING JING POI TI - Association of <em>ANRIL</em> Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation AID - 10.21873/anticanres.14585 DP - 2020 Oct 01 TA - Anticancer Research PG - 5707--5713 VI - 40 IP - 10 4099 - http://ar.iiarjournals.org/content/40/10/5707.short 4100 - http://ar.iiarjournals.org/content/40/10/5707.full SO - Anticancer Res2020 Oct 01; 40 AB - Background/Aim: Genetic variations of the non-coding RNA gene, ANRIL, have been associated with human diseases including cancer, type-2 diabetes, and atherosclerosis. In the present study, we investigated the potential associations of select ANRIL single nucleotide polymorphisms (SNPs) with overall survival and other clinical outcomes in adult patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients and Methods: Genomic DNA was extracted from whole blood samples from 103 adult patients with hematologic malignancies who had received allo-HSCT followed by oral tacrolimus therapy. The genotypes of four select ANRIL SNPs, rs564398, rs1063192, rs2151280, and rs2157719 were determined using qRT-PCR-based genotyping assays. Results: rs2151280 (C-&gt;T) in ANRIL was associated with worse overall survival in these patients (CT/CC vs. TT). Contrarily, rs2151280 and the other select ANRIL SNPs were not associated with death at Day-100 after transplantation, the incidence of graft-versus-host disease (GVHD), acute kidney injury (AKI), and neurotoxicity in the study cohort. Conclusion: rs2151280 represents a potential prognostic biomarker for overall survival in adult patients with hematologic malignancies after allo-HSCT.